Rapid Readout: T-DXd in Patients With HER2+ Unresectable or Metastatic Gastric or GEJ Following a Trastuzumab-Containing Regimen
October 27th 2021
Ronan Kelly, MD, MBA, discusses data from the presentation “Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.” (Van Cutsem et al, ESMO 2021, LBA55)